Cargando…
New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
INTRODUCTION: The most recently approved antiretroviral, the integrase inhibitor dolutegravir (DTG), is described to be a very potent drug with a unique resistance profile, but a certain degree of cross-resistance to RAL or EVG induced drug resistance, which is mediated mainly by integrase mutations...
Autores principales: | Carganico, Andreas, Dupke, Stefan, Ehret, Robert, Berg, Thomas, Baumgarten, Axel, Obermeier, Martin, Walter, Hauke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225390/ https://www.ncbi.nlm.nih.gov/pubmed/25397494 http://dx.doi.org/10.7448/IAS.17.4.19749 |
Ejemplares similares
-
Resistance remains a problem in treatment failure
por: Obermeier, Martin, et al.
Publicado: (2014) -
Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
por: Ehret, Robert, et al.
Publicado: (2014) -
Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014) -
Acute hepatitis C virus (HCV) infection in the setting of HIV coinfection: a single-centre 10-year follow-up
por: Ingiliz, Patrick, et al.
Publicado: (2014) -
The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)